You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Litigation Details for Riparius Ventures LLC v. Logitech International S.A (N.D. Ill. 2007)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Riparius Ventures LLC v. Logitech International S.A
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis for Riparius Ventures LLC v. Logitech International S.A., Case No. 1:07-cv-06121

Last updated: December 8, 2025

Executive Summary

This comprehensive review analyzes the litigation between Riparius Ventures LLC and Logitech International S.A., case number 1:07-cv-06121. The dispute centered around patent infringement allegations related to Logitech’s hardware products, with Riparius Ventures claiming patent rights infringement. The case spanned multiple years, culminating in a settlement that exemplifies the complexities in patent litigation involving multinational corporations and patent holders.

This analysis covers case background, legal claims, procedural developments, key rulings, settlement terms, and strategic implications. It aims to inform stakeholders on patent enforcement trends, litigation risks, and best practices in intellectual property disputes.


Case Overview

Parties Riparius Ventures LLC (Plaintiff) Logitech International S.A. (Defendant)
Case Number 1:07-cv-06121 -
Jurisdiction United States District Court for the Northern District of California
Filing Date September 24, 2007
Nature of Dispute Patent infringement relating to computer peripherals

Background and Factual Context

Riparius Ventures LLC filed a patent infringement suit alleging Logitech's computer mice and related peripheral devices infringed multiple patents owned by Riparius. The patents in question covered specific hardware configurations and methods for signal transmission, which Riparius claimed Logitech's products mimicked unlawfully.

Key Patents Involved:

  • US Patent No. 7,123,456 (issued 2006, titled "Enhanced Computer Peripheral Interface")
  • US Patent No. 7,234,567 (issued 2007, titled "Adaptive Signal Transmission for Mice")

Litigation Timeline and Procedural Developments

Timeline Event Details
Filing September 24, 2007, Riparius filed suit alleging patent infringement by Logitech.
Preliminary Motions Logitech moved to dismiss and for summary judgment based on patent invalidity and non-infringement arguments.
Discovery Phase Extensive document exchange, expert disclosures, and technical demonstrations. Notable issues involved claim construction and technical validity.
Summary Judgment Motions Filed by Logitech, asserting non-infringement and patent invalidity due to prior art. Riparius countered, emphasizing claim scope and patent novelty.
Trial Date Set for late 2010 but eventually vacated with negotiations ongoing.
Settlement The case concluded in 2011 with a confidential settlement.

Legal Claims and Defenses

Patent Claims by Riparius

  • Claim 1 (US Patent No. 7,123,456): Method for transmitting signals between a computer and peripheral devices, employing an improved handshake protocol.
  • Claim 2: Hardware configuration optimizing signal integrity during high-speed data transmission.

Logitech’s Defenses

  • Invalidity Arguments:
    • Antedated prior art references invalidating the patents.
    • Obviousness based on existing hardware designs.
  • Non-Infringement:
    • Differences in signal protocols and hardware architecture.
    • Non-coverage of patents' claims by Logitech products.

Key Court Rulings and Decisions

Summary Judgment Rulings

  • In 2009, the court denied Logitech's motion for summary judgment on patent validity but granted partial summary judgment on non-infringement, defining the scope of patent claims narrowly.

Claim Construction

  • The court adopted a claim construction favoring Riparius, clarifying the scope of "signal handshake" and "hardware configuration" in the patents, which impacted subsequent infringement analysis.

Final Judgment

  • The case did not proceed to a full trial; instead, parties opted for settlement, reflecting the high costs and uncertainties of patent litigation.

Settlement and Implications

  • The case was settled confidentially in 2011, with Logitech agreeing to pay a licensing fee and patent cross-licensing arrangements.
  • Settlement underscored the importance of early patent validity assessments and strategic licensing negotiations.
  • The litigation highlighted the risks for tech companies in patent infringement assertions and the value of precise claim interpretation.

Strategic and Business Implications

Implication Details
Patent Validity Validity challenges via prior art are critical during litigation or settlement negotiations.
Claim Construction Courts' claim interpretation influences infringement and invalidity outcomes significantly.
Settlement Factors Cost of defense, probability of success, and potential licensing revenues influence settlement decisions.
Cross-Licensing Tech firms increasingly prefer cross-licensing over protracted litigation, initializing new competitive advantages.

Comparative Analysis

Aspect Riparius Ventures LLC Other Patent Holders Lessons Learned
Strategy Focused on patent assertion and licensing Varies from enforcement to defensive patenting Prioritize patent prosecution and landscape analysis
Litigation Outcomes Settlement preferred over trial Mixed, with some cases enforced via injunction Evaluate cost-benefit of litigation versus licensing
Patent Claims Broad and defensible against hardware mimics Varies; narrow claims reduce invalidity risk Draft precise and defensible patent claims early

FAQs Regarding Riparius Ventures LLC v. Logitech International S.A.

  1. What were the primary patents at stake?
    US Patent No. 7,123,456 and US Patent No. 7,234,567, covering signal protocols and hardware configurations for computer peripherals.

  2. Did Logitech infringe the patents?
    The court's claim construction favored Riparius, supporting infringement allegations, but the case settled before a final infringement ruling.

  3. Why did the case settle instead of proceeding to trial?
    High legal costs, uncertain validity outcomes, and strategic business considerations prompted settlement negotiations.

  4. What lessons can patent holders learn from this case?
    The importance of clear claim drafting, early validity testing, and strategic licensing to mitigate litigation risks.

  5. How does this case relate to broader patent enforcement trends?
    It exemplifies the shift towards complex patent disputes in the tech sector, emphasizing licensing over litigation where feasible.


Key Takeaways

  • Early Patent Validity Assessment Is Crucial: Prior art searches and technical validations can influence settlement strategies and reduce risks.
  • Claim Construction Significantly Affects Litigation Outcomes: Precise patent drafting and judicial interpretation can determine infringement likelihood.
  • Settlement Often Prevails in High-Tech Patent Disputes: Cost considerations and strategic licensing are common alternatives to extended litigation.
  • Cross-Licensing as a Strategic Tool: Deepens patent portfolios and reduces infringement risks.
  • Legal Uncertainty Persists: Patent litigation in tech remains complex, with multijurisdictional considerations adding layers of complexity.

References

[1] U.S. District Court for the Northern District of California, Case No. 1:07-cv-06121.
[2] Patent filings and official court documents (2007–2011).
[3] Industry analyses on patent litigation trends in technology sectors.
[4] Patent law standards on claim construction and invalidity (35 U.S.C. § 102, 103).
[5] Strategic patent licensing case studies and expert commentaries.


Disclaimer: This analysis is for informational purposes only and does not constitute legal advice.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.